Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2026)

Contineum Therapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $2.9 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 139.85% to $2.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Mar 2026, up 139.85% year-over-year, with the annual reading at $6.4 million for FY2025, 4.83% down from the prior year.
  • Accumulated Expenses came in at $2.9 million for Q1 2026, down from $6.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $6.7 million in Q4 2024 to a low of $959000.0 in Q1 2024.
  • The 4-year median for Accumulated Expenses is $2.5 million (2024), against an average of $3.1 million.
  • Year-over-year, Accumulated Expenses fell 4.83% in 2025 and then skyrocketed 139.85% in 2026.
  • Contineum Therapeutics' Accumulated Expenses stood at $4.4 million in 2023, then soared by 53.04% to $6.7 million in 2024, then dropped by 4.83% to $6.4 million in 2025, then crashed by 55.24% to $2.9 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Accumulated Expenses are $2.9 million (Q1 2026), $6.4 million (Q4 2025), and $2.8 million (Q3 2025).